Introduction {#Sec1}
============

Although major advances have been made in understanding the cellular and molecular bases of inflammatory processes, only a limited number of optimally effective anti-inflammatory drugs are available on the market. Inflammation is involved in numerous pathological conditions, including arthritis, atherosclerosis, the metabolic syndrome, sepsis, allergies, auto-immune diseases, and cancer \[[@CR1]\]. For most of these diseases, neither satisfying treatments nor effective concepts of prevention are available. Moreover, chronic vascular inflammatory diseases are still the main cause of death in the world and according to the World Health Organization (WHO), their incidence is expected to continue rising in the next years \[[@CR2]\].

Inflammation is the body's response to tissue injury, either physical (mechanical or by irradiation), by infectious agents, or by malignant or pathologically altered cells. It is associated with local cytokine production, activation of vascular cells and adhesion and transmigration of leucocytes into the site of injury. Many of the inflammatory processes elicited within vascular and immune cells are regulated by the transcription factor nuclear factor kappa B (NF-κB) \[[@CR3], [@CR4]\]. Major target genes of NF-κB include adhesion molecules, cytokines, growth factors, and enzymes, such as cyclooxygenase-2 (COX-2). Most prominent upstream inducers are pro-inflammatory cytokines, tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and bacterial lipopolysaccharides (LPS). Since it is clear that NF-κB is pivotal for inducing an inflammatory response, counteracting pathways are of high relevance \[[@CR4]\]. Important repressors of NF-κB activation are nuclear receptors, among those the glucocorticoid receptor (GR) \[[@CR5]\], the peroxisome proliferator-activated receptors (PPARs) \[[@CR6]--[@CR8]\], the liver X receptor (LXR) \[[@CR9], [@CR10]\] and the NR4A family of nuclear orphan receptors \[[@CR11]\]. PPARs exert their anti-inflammatory activities mainly by repressing the transactivation of other transcription factors, such as NF-κB or activator protein 1 (AP1), both involved e.g. in the induction of cell adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) \[[@CR12]--[@CR14]\].

Natural products (NPs) have always been an important source of new drug leads \[[@CR15], [@CR16]\]. For decades, drug discovery was successfully fueled from natural sources. The first blockbuster was developed towards the end of the nineteenth century starting from salicylic acid, a compound from the willow tree, successfully marketed after acetylation as Aspirin^®^ \[[@CR17]\]. Another commercially highly successful group of drugs, the statins, originating from *Aspergillus terreus* (lovastatin), marks the outgoing twentieth century \[[@CR18]\]. Analysis of drugs approved by the US FDA between 1981 and 2010 showed that 50 % of all new chemical entities (NCEs) and 64 % of all small-molecule NCEs were NPs, NP-derived compounds, or compounds inspired by NPs \[[@CR19]\]. Moreover, even though many pharmaceutical companies have discontinued their programs of drug discovery from natural sources and have focused mainly on high-throughput screening of predominantly combinatorial synthetic compound libraries throughout the last decades, in the year 2010 half of the 20 small-molecules launched as NCEs on the market were NPs or NP-derived compounds \[[@CR19]\]. This underlines that even today, in the post genomic era, plants, fungi, marine organisms, and microorganisms are still important and effective sources for the development of new drugs or drug leads \[[@CR15]\].

Therefore, the overall aim of the DNTI project was to identify and characterize (chemically and pharmacologically) NPs capable of combating inflammatory processes, specifically in the context of cardiovascular diseases.

Scientific approach of the DNTI project {#Sec2}
=======================================

The DNTI project comprised a unique combination of strategies including the following aspects:The focus on NPs representing a structural diversity, which is significantly higher than that of synthetic compound libraries \[[@CR20]\].The application of in silico tools like pharmacophore-based virtual screening of NP databases or parallel activity profiling to identify promising compounds for pharmacological evaluation, and to provide suggestions for their pharmacological mechanisms of action.The exploitation of traditional knowledge about plants to select interesting candidates for phytochemical and subsequent pharmacological investigation.The usage of plant metabolomics and the correlation with activity data in order to identify compounds most relevant for activity.

Objectives and goals of the project comprised:Target selection with emphasis on pharmacological relevance and suitability for reliable pharmacophore modeling (structural information on the protein or respective ligands),Compilation of information for the selection of promising natural material based on ethnopharmacological knowledge and based on virtually predicted structures of secondary metabolites from plants, fungi, microbes, etc., botanical and genetic authentication of the starting material to ensure reproducibility of the results by identifying confusions, admixtures, contaminants or (endo)symbionts,Identification of bioactive NPs using either a computational or a bioassay-guided isolation approach for a target-oriented or effect-driven discovery process,Pharmacological profiling and mechanistic studies on the molecular level of selected bioactive constituents by multidisciplinary research activities (in vitro, in vivo, in silico assessment),Analytical studies, quality assessment of natural material, and biotechnological support, providing a highly standardized supply of natural material as sources for new lead compounds,Biometric evaluation of candidates via metabolomics, andGeneration of semisynthetic derivatives of natural hit compounds for assessing possible improvements and synthetic up-scaling of leads.

The workflow of the project is outlined in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Workflow of the DNTI project

The project was structured into two periods of 3 years each. The first period (2008--2011) was devoted mainly to screening and the identification of novel NPs with pronounced anti-inflammatory effects. Therefore, at the beginning of the project, the consortium focused largely on target selection, the compilation of information for the selection of promising natural material, and the identification of bioactive NPs using either the computational or the bioassay-guided approach.

The second period (2011--2014) focused more on detailed pharmacological and toxicological profiling and in-depth characterization of interesting NPs, including the determination of the mechanisms of action of those compounds that showed promising in vitro and in vivo activity. In addition to pharmacological profiling and mechanistic studies on the molecular level of selected bioactive constituents, the second period also covered analytical studies, quality assessment of natural materials, organic synthesis and biometric identification of candidates using metabolomics. Most promising leads and their isolated or semisynthetic derivatives were thoroughly investigated in terms of their anti-inflammatory and in vitro toxicological profile.

The comprehensive and multi-facetted research approach required an interdisciplinary consortium of scientists with complementary expertise in the fields of computational, analytical, NP, and synthetic chemistry, in vitro pharmacology, cellular signaling, in vivo pharmacology, biotechnology, molecular botany, and plant conservation as well as cultivation. Thus, the project involved eight groups from six different Austrian universities in Innsbruck, Vienna, and Graz and several external partners. The highly interdisciplinary team avoided duplication of efforts and capitalized on the complementary scientific expertise of the partners, their strong background and previous contributions in the field. Ideas, reagents, new technologies, and personnel were transferred among the participating laboratories and ultimately allowed for a comprehensive analysis of the studied scientific topic.

Organization of the DNTI project {#Sec3}
================================

Based on the key expertise of the different partners and due to management reasons and organizational matters, the DNTI project was organized in nine project parts (PPs), i.e., PP1--PP9 (Table [1](#Tab1){ref-type="table"}).Table 1Overview of the project parts (PPs)PP numberPP titlePP leaderPP1CoordinationH. StuppnerPP2Identification of bioactive natural products by virtual screeningT. Langer\
G. Wolber\
D. SchusterPP3From in silico plant selection to bioactive natural productsH. StuppnerPP4From cell-based assays to molecular mechanismsV. DirschPP5From ethnomedicine to bioactive natural products via bioassay-guided isolationR. BauerPP6Reemerging medicinal plants: bioactivity and biotechnologyB. KoppPP7Medicinal plants: molecular characterization and domesticationC. FranzPP8In vitro and in vivo models of inflammationB. Binder^†^\
V. BochkovPP9Lead-modification of medicinal plant constituents and synthetic lead up-scalingM. Mihovilovic^†^B. Binder---deceased

The major aim of PP1 ("Coordination") was to ensure the success of the overall network project by a smooth, transparent, and effective management. Tasks were to set up the collaboration facilities, to drive the overall research direction of the project, and to coordinate the individual PPs.

PP2 ("Identification of bioactive NPs by virtual screening") was devoted to the generation, application, and refinement of extended computer-assisted methods, such as pharmacophore models, for efficiently identifying NPs with potential anti-inflammatory effects and to predict bioactivities of natural compounds by virtual parallel screening. Within PP2, a pharmacophore model collection for a series of targets from the arachidonic acid cascade (e.g., cytosolic phospholipase A~2~ (cPLA~2~), microsomal prostaglandin E~2~ synthase-1 (mPGES-1), soluble epoxide hydrolase (sEH), and COX), the NF-κB pathway \[e.g., inhibitor of nuclear factor kappa-B kinase-β (IKK-β)\], and the nuclear receptor family (e.g., PPARα, PPARγ, and PPARβ/δ, retinoid X receptor (RXR), farnesoid X receptor (FXR), and LXR) was compiled. The models were experimentally validated and applied to virtually screen NP databases in order to predict promising NPs for isolation and pharmacological investigation. Parallel pharmacophore-based profiling of selected NPs suggested anti-inflammatory mechanisms of action for these compounds. Furthermore, bioactive NPs were docked into the respective ligand binding sites to rationalize compound binding and structure-activity relationships. Additional virtual screening methods (shape-based search, 2D similarity search) were applied as complementary approaches to identify active NPs and suggest possible targets including antitargets that could be responsible for adverse effects. PP2 played a crucial role especially in the first steps of this research project, since it produced initial data for the rational selection of NPs to be isolated and biologically tested. In addition, in silico predictions performed within PP2 guided rationalized synthesis of NP derivatives.

PP3 ("From in silico plant selection to bioactive NPs") aimed to identify anti-inflammatory compounds from natural sources by implementation of virtually predicted ligand-target interactions obtained within PP2 in the pharmacognostic workflow. PP3 provided 3D multiconformational molecule databases containing structures of NPs for the virtual screening process. Hit candidates with predicted interactions with the binding sites of selected targets were evaluated and ranked according to chemical stability, non-toxicity, drug likeness, accessibility, and others. Selected hit candidates were isolated from appropriate natural sources and forwarded to PP4, PP5, and PP8 for assessment of the predicted pharmacological effects. Moreover, hints from traditional medicine were used as a rationale for the selection of natural material worth to be phytochemically investigated using bioassay-guided isolation strategies. Furthermore, proton nuclear magnetic resonance (^1^H-NMR) spectroscopy based metabolomics was applied (a) to identify bioactive constituents of multi-component mixtures providing a rationale for their traditional use, (b) to give insight into the molecular mechanism of action, and overall (c) to discover novel natural lead structures.

The main tasks of PP4 ("From cell-based assays to molecular mechanisms") were (a) to provide pharmacological assays for the bioassay-guided fractionation in order to identify anti-inflammatory NPs and (b) the in-depth pharmacological characterization of hit compounds obtained either from the virtual or the bioassay-guided approach in appropriate cellular systems. Therefore, within PP4, target-oriented (e.g., for activation of PPARα, PPARβ/δ, PPARγ, LXRα, LXRβ, RXRα, and for inhibition of NF-κB and IKK-β) and functional cellular models (e.g., quantification of adhesion molecule expression in endothelial cells, glucose uptake and lipid accumulation by adipocytes, vascular smooth muscle cell (VSMC) proliferation and migration, nitric oxide (NO) release from endothelial cells) were established and provided to pharmacologically evaluate plant extracts and fractions, pure isolated compounds or synthetic derivatives of NPs as well as virtually predicted modulators, derived from the ethnopharmacological approach (PP3, PP5, PP6), the computational approach (PP2, PP3), and total synthesis (PP9). Furthermore, in-depth pharmacological characterization of compounds that have shown in vitro and in vivo activity was carried out in order to determine their mechanism of action.

Within PP5 ("From ethnomedicine to bioactive NPs via bioassay-guided isolation"), plant material especially from traditional Chinese medicine (TCM), which has been traditionally used for anti-inflammatory purposes, was selected and provided. Phytochemical characterization (metabolic profiling), bioassay-guided isolation (in close collaboration with PP4 and PP8), and structural elucidation of active constituents were the major tasks. For additional pharmacological profiling, both cellular (inhibition of leukotriene biosynthesis in human granulocytes and human platelets, inhibition of inducible nitric oxide synthase (iNOS) in macrophages) and enzymatic (inhibition of prostaglandin biosynthesis by COX-1 and COX-2) in vitro assays were performed. Moreover, metabolomics data of selected extracts obtained by liquid chromatography coupled with high-resolution-mass spectrometry (LC-HRMS) and ^1^H-NMR spectroscopy were correlated with anti-inflammatory activity by means of multivariate data analysis to identify active principles.

During the course of PP6 ("Reemerging medicinal plants: bioactivity and biotechnology"), an extensive literature survey for anti-inflammatory plant species without known mode of action was conducted at the beginning of the project. A large number of plant samples were collected in the field and botanically identified. In close cooperation with PP4 and PP8, a screening of crude extracts was performed using cell-based or enzymatic assays. Promising extracts were chosen for characterization and bioassay-guided fractionation, leading to the isolation of active compounds. In addition, data of known NPs, e.g. from the VOLKSMED database \[[@CR21]\], were made available for in silico screening. Moreover, the production of plants, especially endangered species and species that are difficult to propagate, was accomplished through biotechnology, including establishment of gene banks, genotype selection, micropropagation of elite plants, and organ cultures.

The most important input of PP7 ("Medicinal plants: molecular characterization and domestication") was in the fields of plant biodiversity and biosynthesis of NPs. PP7 provided molecular support for the identification and genetic improvement of plants containing novel NPs. Major tasks were authentication of plant material, marker assisted (chemotype) selection of promising plants containing new NPs, and development of conservation strategies for endangered species. Moreover, defined plant material was produced by controlled cultivation and provided for further investigations.

Within PP8 ("In vitro and in vivo models of inflammation"), cellular assays that are complimentary to those provided within PP4 and PP5 were established. To evaluate anti-inflammatory effects of plant extracts and plant-derived compounds, in vitro models to determine the induction of inflammatory cytokines such as interleukin-8 (IL-8) and adhesion molecules such as E-selectin in endothelial cells treated with the inflammatory cytokine TNF-α or the bacterial product LPS were used. Within this PP, the activation of nuclear receptors such as LXR and FXR was also addressed. In addition, PP8 was devoted to mechanistic studies as well as the investigation of the effectiveness of selected pure NPs in models of acute and chronic diseases, including chronic cardiovascular inflammation in mice. Therefore, in vivo models such as the murine femoral artery cuff model and the murine thioglycollate induced peritonitis model were used.

Starting from interesting hit candidates, the key tasks of PP9 ("Lead-modification of medicinal plant constituents and synthetic lead up-scaling") were (a) to develop synthetic routes to some target structures in order to provide sufficient quantities for detailed pharmacological characterization and (b) based on the development of modular synthetic routes, to enable the design of focussed compound libraries in order to assess possible improvements of the initially discovered biological activities. Therefore, within PP9, structural analogs of plant constituents with recognized biological activity were synthesized and up-scaling of the synthetic processes of promising bioactive compounds was established.

During the course of DNTI, several external partners from various countries were also involved in the project. They had different tasks and focuses and supported the network among others by (a) providing purified individual compounds identified as potential hits by the in silico approach, (b) contributing to the pharmacological and toxicological evaluation of selected NPs with biological assays which were not established within the consortium, and (c) supplying plant material for further investigations.

The manifold interfaces between the research areas and the involved PPs contributed in a synergistic way to the different aspects of the respective fields and are shown in Fig. [2](#Fig2){ref-type="fig"}. Detailed information on the network project is provided on the homepage <http://www.uibk.ac.at/pharmazie/pharmakognosie/dnti/>.Fig. 2Overview of research areas including interfaces and involved PPs. PPs written in *bold font* had a major impact, *not bold* ones had a minor impact in the respective area

Selected findings of the DNTI project {#Sec4}
=====================================

The overall aim of the DNTI project to identify and characterize anti-inflammatory NPs was addressed by a unique combination of strategies. By utilizing computational and ethnopharmacological approaches or a combination thereof and by the collaboration of experts from different research fields, NPs with highly promising in vivo and/or in vitro anti-inflammatory activity were identified, which have the potential to serve as novel lead compounds for drug development. Some of the major findings are:

Plumericin from *Himatanthus sucuuba* {#Sec5}
-------------------------------------

*Himatanthus sucuuba* (Spruce) Woodson is used in South American folk medicine to treat inflammatory diseases \[[@CR22]\]. Although fractions have been shown to possess anti-inflammatory activity in vivo \[[@CR23]\], the molecular mechanism of action and the bioactive principles were unknown. Bioassay-guided fractionation of *H. sucuuba* bark material led to the isolation of iridoids, flavonoids, and the lignan pinoresinol. The absolute structure of plumeridoid C (**1**) was resolved by X-ray single crystal structure analysis \[[@CR24]\]. Plumericin (**2**) was identified as an active principle of *H. sucuuba* with potent anti-inflammatory activity. It inhibited NF-κB-mediated transactivation of a luciferase reporter gene with an *IC*~50~ of 1.1 µM and blocked TNF-α-induced expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectin in endothelial cells. Further mechanistic studies were performed on **2**, demonstrating that this new scaffold NF-κB inhibitor exerts its NF-κB-inhibitory effect mainly by suppression of inhibitor of kappa B (IκB) phosphorylation and degradation and also by directly targeting IKK-β. Moreover, **2** suppressed thioglycollate-induced peritonitis in mice. Due to its exceptional potency and in vivo efficacy **2** may be ranked among the most interesting NPs described to date as NF-κB pathway blockers \[[@CR25]\] (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Chemical structures of plumeridoid C (**1**) and plumericin (**2**)

Neolignans from*Magnolia officinalis* {#Sec6}
-------------------------------------

A pharmacophore-based virtual screening of 3D NP databases resulted in the identification of neolignans as putative PPARγ agonists. This was verified by testing the neolignan magnolol (**3**), isolated from the TCM plant *Magnolia officinalis* Rehd. et Wils., and its analogues dieugenol (**4**) and tetrahydrodieugenol (**5**) for effectiveness in an in vitro PPARγ receptor binding assay. The neolignans bound to the PPARγ ligand binding domain with EC~50~ values in the nanomolar range, showing binding patterns highly similar to the clinically used PPARγ agonist pioglitazone. Compounds **4** and **5** selectively activated human PPARγ-, but not human PPARα- or PPARβ/δ-mediated luciferase reporter expression in intact cells. The observed pattern suggested partial PPARγ agonism, which is highly favourable \[[@CR26]\].

The structurally closely related neolignan honokiol (**6**) from *M. officinalis* was virtually predicted to bind to the PPARγ ligand binding pocket as a dimer. Pharmacological investigation in a luciferase reporter assay and with purified PPARγ revealed that **6** acts as partial PPARγ agonist. Further investigations, i.e., stimulation of glucose uptake in adipocytes and adipogenic differentiation in 3T3-L1 pre-adipocytes and mouse embryonic fibroblasts, revealed that **6** stimulates basal glucose uptake similar to pioglitazone, but without inducing adipogenesis, an effect observed with pioglitazone. Furthermore, in vivo studies using diabetic KKAy mice demonstrated that oral application of **6** prevents hyperglycemia and suppresses weight gain. This outstanding non-adipogenic profile suggests **6** as promising novel pharmaceutical lead to counteract metabolic disease, and provides a molecular explanation for the usage of *M. officinalis* in traditional medicine \[[@CR27]\].

For subsequent biological studies, a modular synthetic strategy was developed towards structural analogs of **3** and **6** based on cross coupling chemistry \[[@CR28]\] (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Chemical structures of magnolol (**3**), dieugenol (**4**), tetrahydrodieugenol (**5**), and honokiol (**6**)

Leoligin from Edelweiss (*Leontopodium nivale* ssp. *alpinum*) {#Sec7}
--------------------------------------------------------------

The lignan leoligin (**7**), isolated from the subaerial plant parts of Edelweiss \[*Leontopodium nivale* ssp. *alpinum* (Cass.) Greuter\], was identified as an inhibitor of the proliferation of human umbilical vein endothelial cells (HUVECs) as well as human VSMCs. Moreover, it was shown to potently inhibit neo-intima formation in an in vivo bypass model \[[@CR29]\]. Compound **7** was also virtually profiled and subsequently experimentally assessed for activation of the cholesteryl ester transfer protein (CETP) \[[@CR30]\]. Additionally, potential drug--drug interactions via the cytochrome P450 enzyme system were predicted. Compound **7** was experimentally shown to be a potent CYP3A4 inhibitor, while CYP1A2 and CYP2C9 were only weakly inhibited \[[@CR31]\].

Moreover, a screening for compounds able to stimulate angiogenesis led to 5-methoxyleoligin (**8**), a natural derivative of **7**. Pharmacological analyses revealed that in contrast to **7**, compound **8** stimulated endothelial tube formation, angiogenic sprouting, and angiogenesis in a chicken chorioallantoic membrane assay. Furthermore, in an in vivo rat myocardial infarct model, **8** increased cardiac performance, decreased apoptosis of cardiomyocytes, induced arteriogenesis but not angiogenesis in the infarction area, and diminished the loss of myocardial muscle. This outstanding pharmacological activity renders **8** one of if not the first low molecular weight compound that may lead to an improvement of myocardial function after myocardial infarction \[[@CR32]\].

In order to provide the natural lignan derivatives in sufficient amounts, the production of lignans in hairy root cultures of *L. nivale* ssp. *alpinum* was investigated under different cultivation conditions (elicitation with silver nitrate, sucrose, and others) leading to contents of the pharmacologically active lignans **7** and **8** comparable to those found in Edelweiss from field cultivation \[[@CR33]\]. Alternatively, total synthesis of **7** was achieved in stereoselective fashion \[[@CR34]\]. Key reaction steps of the synthetic route involved lipase mediated kinetic resolution to establish chirality, radical cyclization towards the tetrahydrofuran core ring, as well as a hydroboration-coupling strategy in order to enable diversity oriented design of a compound library of derivatives of **7** (and **8**) (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Chemical structures of leoligin (**7**) and 5-methoxyleoligin (**8**)

Depsides and depsidones from lichen species {#Sec8}
-------------------------------------------

Specific inhibition of mPGES-1, an inflammation induced enzyme, is assumed not to affect the biosynthesis of physiologic prostaglandin (PG)E~2~ and other COX-derived prostanoids. Therefore, inhibitors of mPGES-1 are expected to possess anti-inflammatory activity without leading to unwanted side effects typically associated with COX inhibitors. Aiming to identify novel natural inhibitors of this innovative target, pharmacophore models were developed and experimentally validated \[[@CR35]\]. Virtual screening of NP databases with these pharmacophore models led to the identification of depsides and depsidones from lichen species as potent mPGES-1 inhibitors \[[@CR36]\]. Among them, perlatolic acid (**9**) and imbricaric acid (**10**) from *Cetrelia monachorum* (Zahlbr.) Culb. et Culb. showed strong inhibition of mPGES-1 (*IC*~50~ = 0.4 and 1.9 µM, respectively, on the purified enzyme), 5-lipoxygenase (5-LO) (*IC*~50~ = 1.8 and 5.3 µM, respectively, in a cell-based assay and *IC*~50~ = 0.4 and 3.5 µM, respectively, on the purified enzyme), as well as of TNF-α-induced NF-κB activation (*IC*~50~ = 7.0 and 2.0 µM, respectively, in luciferase reporter cells). The anti-inflammatory effect of **9** was further confirmed in a murine in vivo model of inflammation, in which a significant reduction of thioglycollate-induced recruitment of leukocytes to the peritoneum was demonstrated \[[@CR37]\] (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Chemical structures of perlatolic acid (**9**) and imbricaric acid (**10**)

Benzofurans from *Krameria lappacea* {#Sec9}
------------------------------------

*Krameria lappacea* (Dombey) Burdet et Simpson roots are used in traditional medicine for the treatment of oropharyngeal inflammation. The dichloromethane extract of the root material as well as eleven isolated lignan derivatives exhibited a prominent anti-edema effect in a croton-oil induced mouse ear edema model, comparable to the effect of the positive control indomethacin. Pharmacological investigations of the isolated NPs in different in vitro models revealed the inhibition of several molecular targets by the isolated compounds, i.e., NF-κB, COX-1 and -2, 5-LO, and mPGES-1, as well as antioxidant effects \[[@CR38]\]. Interestingly, among the eleven isolated compounds, only 2-(2,4-dihydroxyphenyl)-5-(*E*)-propenylbenzofuran (**11**) enhanced endothelial nitric oxide synthase (eNOS) activity and NO release in endothelial cells \[[@CR39]\]. To quantify the active lignan derivatives in the roots as well as in Tinctura Ratanhiae, a HPLC method was developed and validated. Analyses of several root and tincture samples showed that (+)-conocarpan (**12**) and ratanhiaphenol II (**13**) are the major compounds, respectively \[[@CR40]\].

Synthetic access to benzofurane-type analogs of the natural compound isolates was achieved by CH-activation \[[@CR41]\]. This is a particularly valuable chemical transformation, as it does not require pre-activation of particular reaction centers but rather exploits intrinsic reactivity differences of C--H bonds in organic structures \[[@CR42]\] (Fig. [7](#Fig7){ref-type="fig"}).Fig. 7Chemical structures of 2-(2,4-dihydroxyphenyl)-5-(*E*)-propenylbenzofuran (**11**), (+)-conocarpan (**12**), and ratanhiaphenol II (**13**)

Isosilybin A from *Silybum marianum* {#Sec10}
------------------------------------

Silymarin represents a concentrated phenolic mixture from milk thistle \[*Silybum marianum* (L.) Gaertn.\] fruits, and is traditionally used in the treatment of a variety of liver diseases \[[@CR43]\]. There is a growing body of evidence supporting a role for PPARs in the pathogenesis of nonalcoholic fatty liver disease \[[@CR44]\]. Therefore, considering the relevant traditional use of silymarin, as well as the existing potential to modulate liver disease by PPAR modulation, it was studied whether silymarin and its purified flavonolignan and flavonoid constituents were able to activate PPARγ. Phytochemical analysis revealed as main silymarin constituents silybin A, silybin B, isosilybin A (**14**), isosilybin B, silychristin, silydianin, and taxifolin. These compounds were evaluated for their ability to cause transactivation of a PPARγ-dependent luciferase reporter gene. As a result of this study, **14** was identified as the first PPARγ-agonist possessing a flavonolignan-type scaffold \[[@CR45]\] (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Chemical structure of isosilybin A (**14**)

Polyacetylenes from *Notopterygium incisum* {#Sec11}
-------------------------------------------

The dichloromethane extract of the roots of *Notopterygium incisum* Ting ex Chang activated PPARγ and showed strong anti-inflammatory activity in vitro. Bioassay-guided fractionation resulted in the isolation of numerous compounds from different classes (coumarins, furanocoumarins, sesquiterpenoids, ferulic acid derivatives, polyacetylenes, and polyacetylene adducts). The crystal structure of the racemic coumarin E-notopterol (**15**) was newly established \[[@CR46]\]. While the coumarins and furanocoumarins were inactive, the polyacetylenes showed activities in the iNOS assay with *IC*~50~ values in the range of 10--30 µM \[[@CR47]\]. Furthermore, the polyacetylenes isolated from *N. incisum* were identified as a novel class of specific partial PPARγ agonists \[[@CR48]\]. In addition, a series of polyacetylene hybrid molecules with sesquiterpene or phenylpropane units were isolated and structurally identified by means of NMR and HRMS. Notoincisol B (**16**) and notoincisol C (**17**) represent two new skeletons. From this series of compounds, notoethers A--C, notoincisol A, as well as **16** showed PPARγ agonistic effects \[[@CR49]\]. A specific DNA barcoding method was developed to authenticate *N. incisum* and to differentiate it from other *Notopterygium* sp. and related Apiaceae \[[@CR47]\] (Fig. [9](#Fig9){ref-type="fig"}).Fig. 9Chemical structures of E-notopterol (**15**), notoincisol B (**16**), and notoincisol C (**17**)

Indirubin-3′-monoxime, a derivative of the dye indirubin {#Sec12}
--------------------------------------------------------

The alkaloid indirubin-3′-monoxime (I3MO) (**18**) is a derivative of the red dye indirubin, which is a component of the TCM Danggui Longhui Wan, and has demonstrated encouraging clinical results in chronic myelocytic leukemia patients \[[@CR50]\]. Compound **18** revealed that it is able to inhibit VSMC proliferation in vitro and neointima formation in vivo in a murine femoral artery cuff model of restenosis. On the cellular level, **18** specifically inhibited signal transducer and activator of transcription 3 (STAT3) phosphorylation in VSMCs, which was shown to contribute to the inhibition of cell proliferation \[[@CR51]\]. 12/15-LO has been identified as a crucial mediator in platelet-derived growth factor (PDGF)-triggered STAT3 activation, which is targeted by **18** \[[@CR52]\] (Fig. [10](#Fig10){ref-type="fig"}).Fig. 10Chemical structure of indirubin-3′-monoxime (I3MO) (**18**)

Compounds from traditional Austrian medicinal plants {#Sec13}
----------------------------------------------------

The VOLKSMED database comprises ethnopharmacological knowledge about plants native to Austria and its adjacent regions. Extracts of 71 herbal drugs traditionally used in Austrian folk medicine (retrieved from the VOLKSMED database) were evaluated for their potential to inhibit NF-κB, and/or activate PPARα and PPARγ. Extracts of more than 50 plants were active in at least one of the three models \[[@CR53]\]. For further bioassay-guided fractionation, extracts were considered that had potent activity and were active in several in vitro and cellular models. An extract of *Melampyrum pratense* L. (Koch) was identified to both stimulate PPARs and inhibit the activation of NF-κB. Bioassay-guided fractionation of this plant extract identified several active flavonoids and iridoids including melampyroside and mussaenoside and the phenolic compound lunularin, which were able to suppress NF-κB and its target genes IL-8 and E-selectin to different extents \[[@CR54]\]. Another interesting herbal drug from the VOLKSMED database that was studied is the rhizome of *Peucedanum ostruthium* (L.) Koch (masterwort), which has been traditionally used in the Alpine region as an ingredient in liqueurs and bitters. To clearly identify *P. ostruthium* and to detect common adulterants in the crude drug, a high-resolution melting curve analysis was performed \[[@CR55]\]. A sensitive and specific HPLC--DAD--MS method was developed for the simultaneous identification and quantification of the main coumarin constituents of this herbal drug \[[@CR56]\]. A dichloromethane extract of the rhizome of *P. ostruthium* was found to inhibit VSMC proliferation, and bioassay-guided fractionation led to the identification of ostruthin (**19**) as the active component mediating this effect \[[@CR57]\] (Fig. [11](#Fig11){ref-type="fig"}).Fig. 11Chemical structure of ostruthin (**19**)

Compounds from traditional Vietnamese medicinal plants {#Sec14}
------------------------------------------------------

In a pharmacological screening approach, 42 extracts of 18 plants used in traditional Vietnamese medicine for the treatment of inflammatory disease conditions were investigated on their ability to inhibit NF-κB and activate nuclear factor-erythroid 2-related factor 2 (Nrf2). Based on the screening results, *Oroxylum indicum* (L.) Kurz, *Eurycoma longifolia* Jack, and *Chromolaena odorata* (L.) King et Rob. were selected for further investigations.

Phytochemical studies on the active dichloromethane extract of the bark of *O. indicum* led to the isolation of ten flavonoids. The flavonoid aglycones oroxylin A (**20**), chrysin (**21**), hispidulin (**22**), and baicalein (**23**) inhibited NF-κB with *IC*~50~ values of 3.9, 7.2, 9.0, and 28.1 µM, while the corresponding glycosides showed no inhibitory activity at a concentration of 30 µM \[[@CR58]\].

Bioassay-guided fractionation of the methanolic extract of *E. longifolia* roots using an NF-κB-driven luciferase reporter gene assay resulted in the identification of a novel quassinoid, eurycomalide C (**24**), and 27 known compounds including 11 quassinoids, six alkaloids, two coumarins, a squalene derivative, a triterpenoid, and six phenolic compounds. C~19~- and C~20~-type quassinoids, canthin-6-one alkaloids, and the alkaloid β-carboline (**25**) were identified as potent NF-κB inhibitors with *IC*~50~ values in the low micromolar range. The quassinoid eurycomalactone (**26**) with an *IC*~50~ of 0.5 µM was identified as the most potent NF-κB inhibitor. In the group of alkaloids, 9-hydroxycanthin-6-one (**27**) possessed the strongest activity (*IC*~50~ = 3.8 µM) \[[@CR59]\].

The dichloromethane extract of *C. odorata* leaves displayed the most potent activity in the NF-κB as well as the Nrf2 assay. Bioassay-guided fractionation led to the isolation of several phytoprostanes. Among those, chromomoric acid C-I (**28**) was identified as a strong Nrf2 activator with a concentration doubling the response of vehicle-treated cells (CD) of 5.2 μM and an inhibitory effect on NF-κB (*IC*~50~ = 6.9 µM) \[[@CR60]\] (Fig. [12](#Fig12){ref-type="fig"}).Fig. 12Chemical structures of oroxylin A (**20**), chrysin (**21**), hispidulin (**22**), baicalein (**23**), eurycomalide C (**24**), β-carboline (**25**), eurycomalactone (**26**), 9-hydroxycanthin-6-one (**27**), and chromomoric acid C-I (**28**)

Compounds from dietary spices {#Sec15}
-----------------------------

Piperine (**29**) and \[6\]-shogaol (**30**) were identified as inhibitors of VSMC proliferation. They originate from black pepper (*Piper nigrum* L.) and ginger (*Zingiber officinale* Roscoe), respectively, which are important dietary spices that are also used in the traditional medicine.

The inhibitory effect of **29** was quantified by determining the metabolic activity of PDGF-activated VSMCs by the resazurin conversion method (*IC*~50~ = 21.6 µM) and by quantifying de novo DNA synthesis by BrdU incorporation. In order to identify compounds with enhanced activity and to deduce a structure activity relationship (SAR), 10 naturally occurring and 15 synthesized derivatives of **29** were additionally analyzed. As a result, several more potent congeners of **29** were identified, in particular the naturally occurring pipertipine, and the two synthetic derivatives (2*E*,4*E*)-*N*,*N*-dibutyl-5-(3,5-dimethoxyphenyl)penta-2,4-dienamide and (*E*)-*N*,*N*-dibutyl-3-(naphtho\[2,3-*d*\]\[1,3\]dioxol-5-yl)acrylamide. These derivatives displayed *IC*~50~ values of 3.4, 6.0, and 7.9 µM, respectively \[[@CR61]\].

Chemical variation of **29** focused on three regions \[[@CR62]\]: substitution pattern at the amide function, structural rigidification of the unsaturated linker region, and modification of the terminal aryl core. Again, a flexible and modular strategy for compound assembly was employed in particular for linker and aryl derivatization based on metal-assisted C--C bond formation reactions \[[@CR63]\].

The inhibitory effect of **30** from *Z. officinale* was also quantified by determination of the total metabolic activity of PDGF-induced VSMCs by the resazurin conversion method (*IC*~50~ = 2.7 μM). Its activity was verified by quantification of de novo DNA synthesis by the BrdU incorporation assay (*IC*~50~ = 3.0 μM). Application of the compound also inhibited the total cellular biomass growth, quantified by crystal violet staining, with an *IC*~50~ of 1.1 μM. Four major bioactive ginger compounds, \[6\]-gingerol, zingerone, \[6\]-paradol, and rac-\[6\]-dihydroparadol, which were less active than **30**, were studied as well. In depth analysis of the inhibitory action of **30** uncovered accumulation of VSMCs in the G0/G1 phase of the cell cycle that was associated with the activation of the Nrf2/HO-1 pathway \[[@CR64]\] (Fig. [13](#Fig13){ref-type="fig"}).Fig. 13Chemical structures of piperine (**29**) and \[6\]-shogaol (**30**)

Metabolic profiling of *Lonicera* and *Clematis* species {#Sec16}
--------------------------------------------------------

Species of the genera *Lonicera* L. and *Clematis* L. are traditionally used for the treatment of inflammation-related diseases. Based on this ethnopharmacological knowledge and the results of a pharmacological screening of a large number of extracts of plants used in TCM, anti-inflammatory species of these genera were selected for proof-of-principle studies in which profiling data obtained by LC--MS analysis and bioactivities of crude extracts were correlated to identify the active constituents \[[@CR65], [@CR66]\].

Key reviews combining the multidisciplinary expertise of the DNTI participants {#Sec17}
------------------------------------------------------------------------------

Making use of the gathered experience and the unique combination of multidisciplinary expertise in DNTI, two reviews were jointly developed, one focusing on NP activators of PPARγ \[[@CR67]\] and another one reviewing established strategies for discovery and resupply of plant-derived bioactive NPs \[[@CR68]\].

Conclusion {#Sec18}
==========

Within the DNTI project, following a unique combination of strategies, a plethora of compounds from natural sources have been identified that are capable of combating inflammatory processes and may act as novel lead structures for the highly demanded anti-inflammatory therapy, especially in the field of cardiovascular diseases. This underlines that NPs represent a valuable source for lead discovery. The complexity of the project demonstrates that NPs research requires a multidisciplinary strategic approach and a complementary scientific expertise.
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